Home Newsfeeds Needham Reinstates Buy on Solid Power, Announces $5 Price Target

Needham Reinstates Buy on Solid Power, Announces $5 Price Target

Needham analyst Chris Pierce reinstates Solid Power (NASDAQ:SLDP) with a Buy and announces $5 price target.

byBenzinga Newsdesk

March 8, 2023

1 minute read

Needham analyst Chris Pierce reinstates Solid Power (NASDAQ:SLDP) with a Buy and announces $5 price target.

Why Jay-Z Thinks That, When It Comes To Legal Weed, ‘Arbitrary Borders Still Demarcate Who Can Benefit’

By Javier Hasse

October 23, 11:09 AM

Jay-Z recently launched a cannabis line, Monogram, in 2020.

GRAMF

4D Molecular Therapeutics Q2 EPS $(0.87) Down From $(0.28) YoY

By Benzinga Newsdesk

August 11, 4:34 PM

4D Molecular Therapeutics (NASDAQ:FDMT) reported quarterly losses of $(0.87) per share. This is a 210.71 percent decrease over losses of $(0.28) per share from the same period last year.

FDMT

Bill Ackman-Axel Springer Controversy Brews: Business Insider Faces Editorial Review Over Accusations Related To Plagiarism Report

By Vandana Singh

January 10, 10:36 AM

Following recent objections by billionaire hedge fund manager Bill Ackman concerning a Business Insider article accusing his celebrity academic wife, Neri Oxman, of academic plagiarism, Axel Springer, Business Insider parent, is reportedly reviewing the process and motivations

NWS

Justice Department Opposes Revealing Details Related To Trump Search Affidavit: Not In ‘Public Interest’

By Shivdeep Dhaliwal

August 16, 12:12 AM

The U.S. Department of Justice (DoJ) is opposing the release of details contained in an affidavit that was used to argue that a probable cause existed for the search of Mar-a-Lago, the Palm Beach, Florida estate belonging to former President Donald Trump.

DWAC

Needham Reinstates Buy on Solid Power, Announces $5 Price Target

Related Posts

Why Jay-Z Thinks That, When It Comes To Legal Weed, ‘Arbitrary Borders Still Demarcate Who Can Benefit’

4D Molecular Therapeutics Q2 EPS $(0.87) Down From $(0.28) YoY

Bill Ackman-Axel Springer Controversy Brews: Business Insider Faces Editorial Review Over Accusations Related To Plagiarism Report

Justice Department Opposes Revealing Details Related To Trump Search Affidavit: Not In ‘Public Interest’